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With a New Delivery
Device for LAA Ligation
Among Various U.S. CentersThe Lariat suture delivery device (SentreHeart,
Redwood City, California) has been used to exclude
the left atrial appendage (LAA). Thus far, there have
not been any randomized controlled trials or large
multicenter experiences reported on the device.
Price et al. made an attempt to describe their
multicenter experience with the Lariat device as
part of the U.S. Transcatheter LAA Ligation Con-
sortium on the safety and efﬁcacy of transcatheter
ligation of the LAA for stroke prevention in atrial
ﬁbrillation (1).
It is an important study that showed how a proce-
dure could have suboptimal outcomes if not executed
properly. In addition, it was fraught with several is-
sues that deserve attention and were not discussed
in the accompanying editorial. Their sample size re-
ﬂected a small portion (7.7%) of the 2,000-plus cases
that were performed in the country at the time of this
publication. Their experience might not be a reﬂec-
tion of the performance of this device across other
centers that have more experience. The majority of
the participant institutions seemed to have limited
experience with this device (mean of 19 cases per
institution). There was no mention of the selection
criteria for the participating centers and the experi-
ence and training of the operators, and the exclusion
and inclusion criteria were not deﬁned. It is not clear
what percentage of these patients underwent the
procedure on a compassionate basis (outside of
standard eligibility as recommended by the manu-
facturer and mentioned in other studies) (2,3). This
muticenter experience is far from being a true
consortium.
The bleeding and major complication rates re-
ported by the investigators are concerning, but these
rates do not reﬂect the clinical experience of other
operators in the country from single-center experi-
ences (3,4). In a quick survey, conducted in 11 U.S.
sites (6 academic centers and 5 community-based
practices with a mean 40 patients per institution)
that included 441 patients, acute closure was seen
in 420 patients (95%); an incidence of bleeding of>500 ml was seen in 10 patients (2.2%); 9 patients
(2%) needed blood transfusions; and 6 patients
(1.3%) needed open heart surgery for cardiac per-
foration. Most of these complications were seen
early on, during the use of a 18-gauge Pajunk nee-
dle (Pajunk Medical Systems, Norcross, Georgia) for
pericardial access. Subsequently, operators switched
to a micropuncture needle in a total of 231 (52.3%)
patients. There were no complications related to
pericardial access. Three hundred sixty-three pa-
tients (82.3%) underwent follow-up transesophageal
echocardiographies, with 32 patients (7.2%) showing
a leak during follow-up transesophageal echocardi-
ography at >1 mm. Eight patients (2%) had delayed
thrombus formation at the ligation site. Five pa-
tients (1.1%) had delayed pericardial effusion, and 9
patients (2%) had delayed pleural effusions. No
deaths were noted in any of these patients. It
should also be noted that the initial results from 1
of the participating centers in the U.S. Transcatheter
LAA Ligation Consortium reported their experience,
which was vastly different from the recent registry.
This discrepancy suggests the wide variation in
adherence to the procedure as previously described
(2,5), patient selection, and evolution of the tech-
nique. In addition, the investigators mentioned the
use of a micropunture needle for pericardial access
but did not indicate the percentage of patients in
which this needle was used. From our survey, the
incidence of using the micropuncture needle for
pericardial access was in 52.3%, with no evidence of
bleeding or any other major complications.
Given the limitations noted from the accompa-
nying editorial and the contrary experience of the
surveyed centers, the results of this study should
be evaluated with caution, because these ﬁndings
might not be reﬂective of the global safety and
effectiveness proﬁle of the Lariat procedure in expe-
rienced hands for appropriately selected patients. A
prospective, rigorous clinical investigation is required
to prove the risk and/or beneﬁt proﬁle of this therapy,
which will be forthcoming in the near future.*Abdi Rasekh, MD
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New Delivery Device for LAA Ligation
Among Various U.S. CentersWe thank Dr. Rasekh and colleagues for their interest
in our multicenter study of transcatheter left atrial
appendage (LAA) closure with the Lariat suture de-
livery device (SentreHeart, Redwood City, California)
(1). They cite concerns about the participating
centers, operator training, and inclusion criteria,
and claim that our study “shows how a procedure
can have suboptimal outcomes if not executed
properly.” However, this assertion is without merit.
At time of the conception of the registry, all U.S.
sites that were performing the Lariat procedure were
identiﬁed with the assistance of the manufacturer
and invited to participate. Centers that collaborated
in data sharing and provided complete data sets were
included. We ﬁnd it intriguing that the authors are
critical of our site selection, yet were invited to
participate and declined (A.R., S.K., A.M., and D.L.),
with the exception of the University of California-San
Francisco (N.B.), which was not included because of
perceived conﬂicts of interest.
All procedures followed the manufacturer’s pro-
tocols. The manufacturer reviewed all cardiac computed
tomograms before the procedure to conﬁrm anatomic
eligibility according to their pre-deﬁned speciﬁcations.
A clinical specialist or other representative employed by
the manufacturer was present during all procedures.
Reﬂecting their technical skill set, several of the opera-
tors involved in the study served as proctors for the
procedure at the request of the manufacturer.
Our registry included, by design, early procedural
experience; proﬁciency may improve with ongoingcollective experience. There was no signiﬁcant rela-
tionship between site volume and procedural success,
and the inclusion of low volume sites cannot fully
explain our ﬁndings.
Dr. Rasekh and colleagues further assert that our
ﬁndings are inconsistent with the clinical experience
of other operators. Since our publication, another
multicenter study has reported safety and efﬁcacy
event rates similar to that of our study, thereby sup-
porting our overall conclusions (2). Dr. Rasekh and
colleagues cite their own “quick survey” that they
claim shows a substantially better safety proﬁle with
the Lariat. The methodological soundness of an
informal survey is unclear, and their ﬁndings must
be subject to peer review before they can be
considered valid. We commend the authors for their
attempt to systematically collect data and look
forward to the publication of their ﬁndings.
Although we observed very high rates of technical
success, our study raises questions about the safety
and the efﬁcacy of the procedure. The authors argue
that safety can largely be addressed with the use of a
micropuncture needle for pericardial access. How-
ever, this would only affect the risk of right ven-
tricular (RV) perforation. Just one-quarter of the
pericardial effusions that occurred in our report were
felt to be secondary to pericardial sheath placement.
Of the 34 adverse events (including several deaths)
associated with the Lariat that were reported in the
Food and Drug Administration MAUDE (Manufacturer
and User Facility Device Experience) database
between January 2012 and April 2014, only 2 were
attributed to RV perforation; the remainder were
LAA perforations, lacerations, or avulsions (3).
Improving pericardial access would not inﬂuence
the incidence of important post-procedural adverse
events, such as stump thrombus, pleural effusion,
and stroke.
The authors correctly state that our study en-
compasses only a fraction of the >2,000 patients
who have been treated with the Lariat. Regrettably,
our small study of 154 patients represents approxi-
mately one-half of the entire peer-reviewed data
set for a device that is being used in the absence of
any clinical trial or a Food and Drug Administration-
approved indication for stroke prevention; however,
it may be associated with substantial morbidity.
A multicenter, randomized trial with independent
oversight is urgently needed to robustly deﬁne the
safety and long-term efﬁcacy of transcatheter LAA
ligation.*Matthew J. Price, MD
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